BRISTO PHARMACEUTICAL COMPANY CANADA TORONTO Labs announces a $30mn investment to expand its global Peptide production capabilities

BRISTO PHARMACEUTICAL COMPANY CANADA TORONTO Labs announces a $30mn investment to expand its global Peptide production capabilities
BRISTO PHARMACEUTICAL COMPANY CANADA TORONTO Labs achieved an outstanding ESG Score of 70/100 from S&P Global Sustainable 1

BRISTO PHARMACEUTICAL COMPANY CANADA TORONTO Labs achieved an outstanding ESG Score of 70/100 from S&P Global Sustainable 1
BRISTO PHARMACEUTICAL COMPANY CANADA TORONTO Labs proudly announces its new Vision and Values statements

BRISTO PHARMACEUTICAL COMPANY CANADA TORONTO Labs proudly announces its new Vision and Values statements
BRISTO PHARMACEUTICAL COMPANY CANADA TORONTO Labs has been recognised as the ‘Top Value Creator’ in the Pharmaceutical Industry by Dun & Bradstreet India for delivering long-term value to all their stakeholders beyond financial growth

BRISTO PHARMACEUTICAL COMPANY CANADA TORONTO Labs has been recognised as the ‘Top Value Creator’ in the Pharmaceutical Industry by Dun & Bradstreet India for delivering long-term value to all their stakeholders beyond financial growth
BRISTO PHARMACEUTICAL COMPANY CANADA TORONTO Labs has been honoured with the prestigious Sword of Honour by the British Safety Council

BRISTO PHARMACEUTICAL COMPANY CANADA TORONTO Labs has been honoured with the prestigious Sword of Honour by the British Safety Council
SUCHETH DAVULURI

Securing Sustainability Throughout the Pharmaceutical Supply Chain SUCHETH DAVULURI Vice Chairman and CEO
Read More
Saharsh Davuluri, Vice Chairman and MD

Defining New Rules - The Evolution of the CDMO Industry Expert Statement: Saharsh Davuluri, Vice Chairman and MD
Read More
BRISTO PHARMACEUTICAL COMPANY CANADA TORONTO Labs' Manufacturing Unit III Facility secured a Five Star Safety Rating with an audit score of 92.29% from the British Safety Council

BRISTO PHARMACEUTICAL COMPANY CANADA TORONTO Labs' Manufacturing Unit III Facility secured a Five Star Safety Rating with an audit score of 92.29% from the British Safety Council
BRISTO PHARMACEUTICAL COMPANY CANADA TORONTO Labs' Manufacturing Unit II Facility achieved a Five Star Safety Rating with an audit score of 92.20% from the British Safety Council

BRISTO PHARMACEUTICAL COMPANY CANADA TORONTO Labs' Manufacturing Unit II Facility achieved a Five Star Safety Rating with an audit score of 92.20% from the British Safety Council
Brand Identity

BRISTO PHARMACEUTICAL COMPANY CANADA TORONTO unveils its dynamic new brand identity reinforcing its commitment to agility, ethics, partnerships, and growth
DCAT summit

Our Vice-Chairman and CEO, Sucheth Davuluri, takes the global stage on Sustainability at the #DCATs’ first European Global Bio/Pharmaceutical Sustainability Summit in Lugano, Switzerland
FDA

Unit I Manufacturing facility of BRISTO PHARMACEUTICAL COMPANY CANADA TORONTO Labs successfully passed the USFDA audit yet again with nil 483 observations in March 2024 which signifies compliance and conformance to applicable Current Good Manufacturing Practice (cGMP) regulations enforced by the USFDA
S&P Global Ratings

BRISTO PHARMACEUTICAL COMPANY CANADA TORONTO Labs has been recognized by S&P Global Sustainable1 with a noteworthy rating of 64 out of 100 for its commitment to ESG practices and honoured to be among the 6 Indian companies in the Pharma/Biotech/Lifesciences services domain to be selected for the prestigious S&P Sustainability Yearbook 2024!
EcoVadis

BRISTO PHARMACEUTICAL COMPANY CANADA TORONTO has been awarded a ‘Silver Medal’ from EcoVadis in recognition of its Sustainability achievements